Molecular genetics of breast cancer progression

被引:82
作者
Ingvarsson, S [1 ]
机构
[1] Univ Hosp Iceland, Dept Pathol, Reykjavik, Iceland
关键词
breast cancer; tumor progression; oncogene; tumor suppressor gene; amplification; deletion; mutation; loss of heterozygosity;
D O I
10.1006/scbi.1999.0124
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Somatic changes in the genome of breast cancer cells include amplifications, deletions and gene mutations. Several chromosome regions harboring known oncogenes are found amplified in breast tumors. Despite the high number of chromosome regions deleted in breast tumors the functional relationship to known genes at these locations and cancer growth is mainly undiscovered. Mutations in two tumor suppressor genes (TSG) have been described in a subset of breast carcinomas. These TSG are the TP53, encoding the p53 transcription factor, and the CDH1, encoding the cadherin cell adhesion molecule. Breast tumors of patients with a germ-line mutation in the BRCA1 or BRCA2 gene have an increase of additional genetic defects compared with sporadic breast tumors. This higher frequency of genetic aberrations could pinpoint genes that selectively promote tumor progression in individuals predisposed to breast cancer due to BRCA1 or BRCA2 germ-line mutations. Accumulation of somatic genetic changes during tumor progression map follow a specific and more aggressive pathway of chromosome damage in these individuals. Although the sequence of molecular events in the progression of breast tumor is poorly understood the detected genetic alterations fit the model of multistep carcinogenesis in both sporadic and hereditary breast cancer. This review will focus on the genetic lesions within the breast cancer cell.
引用
收藏
页码:277 / 288
页数:12
相关论文
共 156 条
[1]   Inherited BRCA2 mutation associated with high grade breast cancer [J].
Agnarsson, BA ;
Jonasson, JG ;
Björnsdottir, IB ;
Barkardottir, RB ;
Egilsson, V ;
Sigurdsson, H .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 47 (02) :121-127
[2]  
Ahmadian M, 1997, CANCER RES, V57, P3664
[3]  
ALDAZ CM, 1995, CANCER RES, V55, P3976
[4]   OVEREXPRESSION OF THE C-ERBB-2 ONCOPROTEIN - WHY DOES THIS OCCUR MORE FREQUENTLY IN DUCTAL CARCINOMA INSITU THAN IN INVASIVE MAMMARY-CARCINOMA AND IS THIS OF PROGNOSTIC-SIGNIFICANCE [J].
BARNES, DM ;
BARTKOVA, J ;
CAMPLEJOHN, RS ;
GULLICK, WJ ;
SMITH, PJ ;
MILLIS, RR .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :644-648
[5]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[6]   Multistep carcinogenesis of breast cancer and tumour heterogeneity [J].
Beckmann, MW ;
Niederacher, D ;
Schnurch, HG ;
Gusterson, BA ;
Bender, HG .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1997, 75 (06) :429-439
[7]  
BERGTHORSSON JT, 1995, HUM GENET, V96, P437
[8]  
BERGTHORSSON JT, 1995, CLIN GENET, V47, P305
[9]   Chromosome imbalance at the 3p14 region in human breast tumours:: High frequency in patients with inherited predisposition due to BRCA2 [J].
Bergthorsson, JT ;
Johannsdottir, J ;
Jonasdottir, A ;
Eiriksdottir, G ;
Egilsson, V ;
Ingvarsson, S ;
Barkardottir, RB ;
Arason, A .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (01) :142-147
[10]  
Berx G, 1996, ONCOGENE, V13, P1919